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Abstract
Background: It has been recommended by the American Society of Clinical Oncology and the
American Society of Reproductive Medicine that options to preserve fertility be presented at the
outset of treatment for cancer. This recommendation may have arisen, in part, to the increasing
survival of patients with cancer and the realization that certain forms of cancer treatment can lead
to infertility. One option for these patients, particularly those with ethical or religious objections
to freezing embryos is oocyte cryopreservation. However universal acceptance of these
procedures has yet to be established, most likely due to a poor history of success and concerns
that there has yet to be a comprehensive approach to evaluating these techniques. In light of this,
a registry of patients undergoing oocyte cryopreservation, called the HOPE registry, is being
implemented.
Discussion: The intent of the HOPE Registry is to enroll approximately 400 women of
reproductive age who will undergo thawing/warming of oocytes and subsequent transfer. Data
from the patients enrolled will be collected via a uniform, standardized form and will document
important parameters such as demographics, laboratory procedures and outcomes, including
following the outcomes of babies born for one year after birth. The results of the registry will be
published on a yearly basis.
Summary: A patient registry has been established in order to systematically document the
techniques and outcomes of oocyte cryopreservation procedures. The results will be published in
order to provide a widely accessible resource that will allow patients who are considering these
procedures validated information in order to make informed decisions as to how their treatment
will proceed.
Background
The American Cancer Society recently reported a 32%
increase in cancer survival rates for all cancers diagnosed
from 1996 and 2003 [1]. In the past five years, the number
of novel cancer treatments has increased over 50%, and it
is estimated that >1,400 new drug applications for cancer
treatment will be submitted in 2008 [2]. With heightened
public awareness, more aggressive screening and treat-
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steadily, allowing more patients to look forward to a near-
normal life after cancer.
Unfortunately, cancer treatment often results in infertility
[3]. For example, Goodwin et al. estimated that 53 to 89%
of breast cancer patients treated with chemotherapy
undergo premature menopause, and that the risk for pre-
mature menopause was found to be strongly associated
with the age of the patient and the use of systemic chem-
otherapy [4]. The use of alkylating agents has been shown
to increase the risk of premature ovarian failure nine-fold
[5].
These findings have led the American Society of Clinical
Oncology and the American Society for Reproductive
Medicine to issue guidelines recommending that the
potential effect of cancer treatment on fertility and
options to preserve fertility be presented to the patient in
the initial stages of treatment [6,7]. One of the suggested
options for fertility preservation is oocyte cryopreserva-
tion. Although considered an experimental procedure,
oocyte cryopreservation is available, with institutional
review board (IRB) approval. It represents one of the few
viable options for childbearing in reproductive-aged
women undergoing cancer treatment, particularly in
patients without a partner, or who have ethical or reli-
gious objections to embryo freezing [6].
Historically, oocyte cryopreservation has been hampered
by poor oocyte survival. However, in recent years, the
number of pregnancies resulting from fertilization of
thawed/warmed oocytes has increased [[8-12], and [13]].
This success is due to a better understanding of oocyte
physiology, the utilization of improved media and the
implementation of new and innovative techniques [[14-
17], and [18]].
Although the precise number of children resulting from
cryopreserved oocytes is unknown, it is estimated that
over 475 children have been born worldwide from
oocytes that were frozen/vitrified and thawed/warmed,
with no apparent increases in adverse postnatal outcomes
such as low birth weight or an increased incidence of con-
genital anomalies [19,20].
However, despite these reassuring reports there are still
concerns [[21-23], and [24]]. One of the contributing fac-
tors may be the lack of a comprehensive approach to eval-
uating the safety and efficacy of the use of cryopreserved
oocytes. These concerns have been elucidated by recent
guidelines and reports issued by ASRM's Committees
report on this topic, which contend that, to date, the
number of patients treated with oocyte cryopreservation,
is inadequate to determine if the procedure has an effect
on the development of children [25], and that because
data is limited, the procedure should not be marketed as
a method to defer reproductive aging [26]. Nonetheless,
many women understandably have interest in this emerg-
ing technology and view oocyte cryopreservation as a
strategy that may help them to realize their longer-term
reproductive goals [27].
To date, there has been no systematic effort in the United
States to collect outcomes of oocyte cryopreservation
cycles on an ongoing basis. For this reason EMD Serono,
Inc. (Rockland, MA, USA [an affiliate of Merck KGaA,
Darmstadt, Germany]) is proposing the creation of a
patient registry to track the safety and efficacy of oocyte
cryopreservation procedures. Systematic collection of the
data generated in cycles utilizing these procedures across
a variety of clinics is critical to validate the technique and
move the concept of oocyte cryopreservation from an
experimental procedure to a proven and safe technique,
thereby establishing this as a viable treatment option for
fertility preservation.
The aim of Human Oocyte Preservation Experience
(HOPE) Registry is to prospectively and systematically
track the outcome of oocyte cryopreservation cycles to val-
idate (1) the efficacy of techniques to freeze/vitrify and
thaw/warm oocytes and (2) the safety of these procedures,
in relation to the babies resulting from cryopreserved
oocytes.
The HOPE Registry is a phase IV, prospective, multi-
center, observational oocyte cryopreservation patient reg-
istry. Consistent with definitions and guidelines from the
United States Agency for Healthcare Research and Quality,
the HOPE Registry is a health services registry, an "organ-
ized system that uses observational study methods to col-
lect uniform data to evaluate specified outcomes for a
population defined by a particular disease, condition or
exposure, and that serves one or more predetermined sci-
entific, clinical, or policy purposes [28]." The data is pur-
pose-driven and will be collected in a naturalistic manner.
Patient management will be agreed upon by the caregiver
and the patient together and, as such, there will be a
defined ovarian stimulation protocol for each individual
patient enrolled in the registry. The HOPE registry, like
any other phase IV study, will follow a strict study proto-
col for patient enrollment and data collection, and will be
listed on clinicaltrials.gov.
The goal of the three-year registry is to enroll approxi-
mately four hundred (400) women of reproductive age
who will undergo thawing/warming of oocytes and subse-
quent embryo transfer. A pilot phase of The HOPE Regis-
try opened in May 2008; formal enrollment is planned to
begin in November 2008 (ASRM meeting, San Francisco,Page 2 of 4
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consent prior to enrollment in the registry. Local ethics
committee or IRB approval will be required for each par-
ticipating center, and the registry will be conducted
according to the principles of good clinical practice and
the Declaration of Helsinki.
Data will be collected, according to the protocol, via uni-
form, standardized forms for every enrolled patient and
will continue for an additional 2 years to obtain birth out-
comes from patients who achieved pregnancy during the
third year. The HOPE Registry will be open to all investi-
gators who would like to enroll, with the only require-
ment being the recording of data from the frozen/thawed
oocytes that will be fertilized, and the culture and transfer
of resulting embryos. During the course of the study pro-
spective data will be entered in electronic case report
forms, including demographics, controlled ovarian stim-
ulation protocols, laboratory procedures to freeze and
thaw oocytes, as well as embryo culture methods, embryo
transfer procedures, implantation rates, biochemical and
clinical pregnancy results, miscarriage and live birth rates.
Child health and development after birth and at twelve
(12) months of age will also be collected. Data related
with genetic screening (preimplantation genetic diagnosis
[PGD], amniocentesis, chorionic villus sampling, cord
blood cells, etc.) will be utilized to monitor the normality
of the genetic makeup of children born from oocyte cryo-
preservation cycles and to compare it with babies born
from other established ART techniques.
The outcomes of all collected variables will be evaluated
according to a pre-defined statistical analysis plan, and the
cumulative results will be presented and discussed during
an annual investigators' meeting. Following each meeting,
the registry outcomes will be published so as to provide a
widely accessible resource for patients and their caregivers
regarding the efficacy of the different cyropreservation
techniques, as well as the postnatal outcomes of the
babies born from embryos generated from frozen/thawed
oocytes.
Discussion
The HOPE Registry will be the first prospective US registry
to validate the efficacy and safety of oocyte cryopreserva-
tion techniques being utilized under IRB approval.
Through the HOPE Registry, a real-world view of oocyte
cryopreservation will be obtained, and with it, answers to
many unresolved questions from healthcare providers
and their patients who utilize this technique to preserve
fertility for a variety of reasons. In the future, oocyte cryo-
preservation may become a tool for successfully preserv-
ing female gametes, facilitating the formation of oocyte
cryobanks that transform the paradigm of oocyte dona-
tion, thereby bringing hope to women who would other-
wise have no option for childbearing.
Conclusion
The preservation of fertility has become an important
issue, particularly in light of increasing survival rates in
adolescent women and women of childbearing age with
cancer, as the treatments can often impair fertility. Oocyte
cryopreservation is one option for patients who have eth-
ical or religious objections to embryo freezing. Unfortu-
nately, the development of oocyte cryopreservation
techniques has been hampered by a lack of a comprehen-
sive approach to evaluate the safety and efficacy of these
procedures. The present paper describes the establishment
of the HOPE Registry, an endeavor to prospectively and
systematically track the outcome of oocyte cryopreserva-
tion cycles.
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